Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Saved in:

Bibliographic Details
Main Authors:	G. Lyrarakis, S. Bouros, A. Anastasopoulou, A. Gkoufa, P. Diamantopoulos, H. Gogas, D. Ziogas
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001447
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
by: Panagiotis T. Diamantopoulos, et al.
Published: (2025-04-01)

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
by: John Haanen, et al.
Published: (2020-10-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Gut markers for metastatic melanoma receiving immunotherapy
by: Guoping Ou, et al.
Published: (2025-07-01)

Pembrolizumab Plus Lenvatinib for Metastatic Renal Cell Carcinoma in a Patient on Hemodialysis
by: Shimpei Yamashita, et al.
Published: (2025-05-01)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
by: Paolo Antonio Ascierto, et al.
Published: (2020-10-01)

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
by: Ting Chen, et al.
Published: (2024-07-01)

Marked Erythroblast Haemophagocytosis in Association With Immunotherapy for Metastatic Melanoma
by: Tamasine Stewart, et al.
Published: (2025-06-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Granulomatous reaction after facial filler during metastatic melanoma treatment with immunotherapy: a case report
by: Luana Pizarro Meneghello, et al.
Published: (2025-03-01)

Combined stereotactic radiation therapy and immunotherapy for metastatic uveal melanoma
by: Valeria V. Nazarova, et al.
Published: (2025-05-01)

A case of delayed onset immune-related optic neuritis after combined immunotherapy treatment for metastatic melanoma
by: Z. Beselaar, et al.
Published: (2024-01-01)

IMMUNOTHERAPY FOR MELANOMA
by: E. A. Borobova, et al.
Published: (2017-09-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
by: Magdalena K. Zielińska, et al.
Published: (2025-02-01)

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
by: Ilya Tsimafeyeu, et al.
Published: (2025-04-01)

Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab
by: A. Pawsey, et al.
Published: (2025-05-01)

Different tumour-resident memory T-cell subsets regulate responses to anti-PD-1 and anti-CTLA-4 cancer immunotherapies
by: Isabelle Damei, et al.
Published: (2025-07-01)

A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
by: Patrick Hwu, et al.
Published: (2016-09-01)

A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy
by: Yan Xu, et al.
Published: (2025-02-01)

Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
by: Erica Martel, et al.
Published: (2025-01-01)

Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring combined anti-PD-L1/anti-CTLA-4 immunotherapy effects in a murine melanoma model with immunohistochemical validation.
by: Felix L Herr, et al.
Published: (2025-01-01)

Immunotherapy in Metastatic Mucosal Melanoma with Disseminated Intravascular Coagulation: A Case of Success
by: Helena Luna Pais, et al.
Published: (2021-01-01)

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy
by: Bolanle Gbadamosi, et al.
Published: (2018-01-01)

Erratum to: A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1
by: Patrick Hwu, et al.
Published: (2017-08-01)

Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab
by: Shigehira Saji, et al.
Published: (2020-10-01)

USP5-Mediated PD-L1 deubiquitination regulates immunotherapy efficacy in melanoma
by: Jiaheng Xie, et al.
Published: (2025-07-01)

Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
by: Weihao Zhang, et al.
Published: (2025-06-01)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01)

Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab
by: Sahana Somasegar, et al.
Published: (2025-04-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
by: Zongyu Liu, et al.
Published: (2025-01-01)

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression
by: Paul G. Pavicic, et al.
Published: (2023-12-01)

Immunotherapy and delivery systems for melanoma
by: Hui Liu, et al.
Published: (2024-12-01)

Progress and challenges in melanoma immunotherapy
by: LIN Jing, et al.
Published: (2025-07-01)

Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation
by: Ming Zhao, et al.
Published: (2025-08-01)

Association of Antibiotics and Other Drugs with Clinical Outcomes in Metastatic Melanoma Patients Treated with Immunotherapy
by: Manish D. Angrish, et al.
Published: (2021-01-01)

Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy
by: Jeffrey Sosman, et al.
Published: (2024-11-01)

Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report
by: Koji Yasuda, et al.
Published: (2017-08-01)